Prescribing information

 

Key efficacy data for LUCENTIS in the treatment of visual impairment due to DMO.

LUCENTIS: 10 years of experience in DMO*

In 2011, LUCENTIS became the first approved anti-VEGF for visual impairment due to DMO.

Large image showing 10-year timeline for the 10-year anniversary for Lucentis' indication in DMO, showing 5 major milestones.


What has been made possible?

Ayad Al Bermani from University Hospital of Wales gave his view on the impact LUCENTIS had on the treatment landscape for DMO* patients.

 

 

Increase in patients’ independent activities
 

12 months after initiating ranibizumab for vision impairment from centre-involved DMO, patients not driving at initiation of treatment were more likely to report driving and have driving-eligible visual acuity of 20/40 or better.‡5
 

Patient-reported quality of life has increased
 

Higher increase in patient-reported health-related QOL than laser treatment.6
 

Today we can not only stabilise, but improve vision
 

Patients are able to achieve substantial improvements in vision, rather than stabilisation alone.6
 

Circlular icons with text saying '2-year T&E' and '5-year T&E' on them.
Circlular icons with text saying '2-year T&E' and '5-year T&E' on them.
 

LUCENTIS Treat & Extend delivered real-world results comparable to those seen in clinical trials2,7

 

 


Three circlular icons with text saying '1-year PRN', '2-year PRN' and '5-year PRN' on them.
Three circlular icons with text saying '1-year PRN', '2-year PRN' and '5-year PRN' on them.
Three circlular icons with text saying '1-year PRN', '2-year PRN' and '5-year PRN' on them.
 

LUCENTIS Treat & Extend delivered real-world results comparable to those seen in clinical trials2,7

 

 


 

*LUCENTIS® 0.5 mg is indicated in adults for the treatment of visual impairment due to diabetic macular oedema (DMO).
Once maximum VA is achieved and/or there are no signs of disease activity.
Equivalent to 6/12 on the Snellen Scale as the UK minimum standard for driving vision.12,13

BCVA, best-corrected visual acuity; DMO, diabetic macular oedema; PAH, Princess Alexandra Hospital; PDR, proliferative diabetic retinopathy; PRN, pro re nata; T&E, treat & extend; VA, visual acuity.

 

References 

  1. Lucentis® Summary of Product Characteristics history.     
  2. Dorairaj E, et al. Abstract presented at European Society of Cataract & Refractive Surgeons (ESCRS), 10–12 February 2017, Maastricht, The Netherlands.
  3. Prakash PR, et al. Poster presented at The Royal College of Ophthalmology Congress 2021. 
  4. Mitchell P, et al. PLoS ONE 2020;15(6):e0233595.
  5. Bressler NM, et al. JAMA Ophthalmol 2016;134(2):160–166.
  6. Mitchell P, et al. Ophthalmology 2011;118(4):615–625.
  7. Prünte C, et al. Br J Ophthalmol 2016;100:787–795.
  8. Lucentis® Summary of Product Characteristics.
  9. Elman MJ, et al. Ophthalmology 2015;122(2):375–381. 
  10. Elman MJ, et al. Ophthalmology 2010;117(6):1064–1077.
  11. Elman MJ, et al. Ophthalmology 2011;118(4): 609–614.
  12. Driving eyesight rules. UK Government. Available at: https://www.gov.uk/driving-eyesight-rules Accessed October 2021.
  13. Conversion table for visual acuity. Available at: https://www.nidek-intl.com/visual_acuity.html Accessed October 2021.
Rate this content: 
No votes yet
UK | October 2021 | 147224
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]